tetano
Editor, Senior Moderator
BMJ
. 2023 May 23;381:e074521.
doi: 10.1136/bmj-2022-074521. Adverse outcomes of SARS-CoV-2 infection with delta and omicron variants in vaccinated versus unvaccinated US veterans: retrospective cohort study
Amy Sb Bohnert[SUP] 1 2 [/SUP], Kyle Kumbier[SUP] 3 [/SUP], Mazhgan Rowneki[SUP] 4 [/SUP], Ashwin Gupta[SUP] 3 5 [/SUP], Kristina Bajema[SUP] 4 [/SUP], Denise M Hynes[SUP] 4 6 7 [/SUP], Elizabeth Viglianti[SUP] 3 5 [/SUP], Ann M O'Hare[SUP] 8 9 [/SUP], Thomas Osborne[SUP] 10 11 [/SUP], Edward J Boyko[SUP] 12 [/SUP], Yinong Young-Xu[SUP] 13 14 [/SUP], Theodore J Iwashyna[SUP] 15 [/SUP], Matthew Maciejewski[SUP] 16 17 [/SUP], Richard Schildhouse[SUP] 3 5 [/SUP], Derek Dimcheff[SUP] 3 5 [/SUP], George N Ioannou[SUP] 18 19 [/SUP]
Affiliations
Objectives: To determine the association between covid-19 vaccination types and doses with adverse outcomes of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection during the periods of delta (B.1.617.2) and omicron (B.1.1.529) variant predominance.
Design: Retrospective cohort.
Setting: US Veterans Affairs healthcare system.
Participants: Adults (≥18 years) who are affiliated to Veterans Affairs with a first documented SARS-CoV-2 infection during the periods of delta (1 July-30 November 2021) or omicron (1 January-30 June 2022) variant predominance. The combined cohorts had a mean age of 59.4 (standard deviation 16.3) and 87% were male.
Interventions: Covid-19 vaccination with mRNA vaccines (BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna)) and adenovirus vector vaccine (Ad26.COV2.S (Janssen/Johnson & Johnson)).
Main outcome measures: Stay in hospital, intensive care unit admission, use of ventilation, and mortality measured 30 days after a positive test result for SARS-CoV-2.
Results: In the delta period, 95 336 patients had infections with 47.6% having at least one vaccine dose, compared with 184 653 patients in the omicron period, with 72.6% vaccinated. After adjustment for patient demographic and clinical characteristics, in the delta period, two doses of the mRNA vaccines were associated with lower odds of hospital admission (adjusted odds ratio 0.41 (95% confidence interval 0.39 to 0.43)), intensive care unit admission (0.33 (0.31 to 0.36)), ventilation (0.27 (0.24 to 0.30)), and death (0.21 (0.19 to 0.23)), compared with no vaccination. In the omicron period, receipt of two mRNA doses were associated with lower odds of hospital admission (0.60 (0.57 to 0.63)), intensive care unit admission (0.57 (0.53 to 0.62)), ventilation (0.59 (0.51 to 0.67)), and death (0.43 (0.39 to 0.48)). Additionally, a third mRNA dose was associated with lower odds of all outcomes compared with two doses: hospital admission (0.65 (0.63 to 0.69)), intensive care unit admission (0.65 (0.59 to 0.70)), ventilation (0.70 (0.61 to 0.80)), and death (0.51 (0.46 to 0.57)). The Ad26.COV2.S vaccination was associated with better outcomes relative to no vaccination, but higher odds of hospital stay and intensive care unit admission than with two mRNA doses. BNT162b2 was generally associated with worse outcomes than mRNA-1273 (adjusted odds ratios between 0.97 and 1.42).
Conclusions: In veterans with recent healthcare use and high occurrence of multimorbidity, vaccination was robustly associated with lower odds of 30 day morbidity and mortality compared with no vaccination among patients infected with covid-19. The vaccination type and number of doses had a significant association with outcomes.
. 2023 May 23;381:e074521.
doi: 10.1136/bmj-2022-074521. Adverse outcomes of SARS-CoV-2 infection with delta and omicron variants in vaccinated versus unvaccinated US veterans: retrospective cohort study
Amy Sb Bohnert[SUP] 1 2 [/SUP], Kyle Kumbier[SUP] 3 [/SUP], Mazhgan Rowneki[SUP] 4 [/SUP], Ashwin Gupta[SUP] 3 5 [/SUP], Kristina Bajema[SUP] 4 [/SUP], Denise M Hynes[SUP] 4 6 7 [/SUP], Elizabeth Viglianti[SUP] 3 5 [/SUP], Ann M O'Hare[SUP] 8 9 [/SUP], Thomas Osborne[SUP] 10 11 [/SUP], Edward J Boyko[SUP] 12 [/SUP], Yinong Young-Xu[SUP] 13 14 [/SUP], Theodore J Iwashyna[SUP] 15 [/SUP], Matthew Maciejewski[SUP] 16 17 [/SUP], Richard Schildhouse[SUP] 3 5 [/SUP], Derek Dimcheff[SUP] 3 5 [/SUP], George N Ioannou[SUP] 18 19 [/SUP]
Affiliations
- PMID: 37220941
- DOI: 10.1136/bmj-2022-074521
Objectives: To determine the association between covid-19 vaccination types and doses with adverse outcomes of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection during the periods of delta (B.1.617.2) and omicron (B.1.1.529) variant predominance.
Design: Retrospective cohort.
Setting: US Veterans Affairs healthcare system.
Participants: Adults (≥18 years) who are affiliated to Veterans Affairs with a first documented SARS-CoV-2 infection during the periods of delta (1 July-30 November 2021) or omicron (1 January-30 June 2022) variant predominance. The combined cohorts had a mean age of 59.4 (standard deviation 16.3) and 87% were male.
Interventions: Covid-19 vaccination with mRNA vaccines (BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna)) and adenovirus vector vaccine (Ad26.COV2.S (Janssen/Johnson & Johnson)).
Main outcome measures: Stay in hospital, intensive care unit admission, use of ventilation, and mortality measured 30 days after a positive test result for SARS-CoV-2.
Results: In the delta period, 95 336 patients had infections with 47.6% having at least one vaccine dose, compared with 184 653 patients in the omicron period, with 72.6% vaccinated. After adjustment for patient demographic and clinical characteristics, in the delta period, two doses of the mRNA vaccines were associated with lower odds of hospital admission (adjusted odds ratio 0.41 (95% confidence interval 0.39 to 0.43)), intensive care unit admission (0.33 (0.31 to 0.36)), ventilation (0.27 (0.24 to 0.30)), and death (0.21 (0.19 to 0.23)), compared with no vaccination. In the omicron period, receipt of two mRNA doses were associated with lower odds of hospital admission (0.60 (0.57 to 0.63)), intensive care unit admission (0.57 (0.53 to 0.62)), ventilation (0.59 (0.51 to 0.67)), and death (0.43 (0.39 to 0.48)). Additionally, a third mRNA dose was associated with lower odds of all outcomes compared with two doses: hospital admission (0.65 (0.63 to 0.69)), intensive care unit admission (0.65 (0.59 to 0.70)), ventilation (0.70 (0.61 to 0.80)), and death (0.51 (0.46 to 0.57)). The Ad26.COV2.S vaccination was associated with better outcomes relative to no vaccination, but higher odds of hospital stay and intensive care unit admission than with two mRNA doses. BNT162b2 was generally associated with worse outcomes than mRNA-1273 (adjusted odds ratios between 0.97 and 1.42).
Conclusions: In veterans with recent healthcare use and high occurrence of multimorbidity, vaccination was robustly associated with lower odds of 30 day morbidity and mortality compared with no vaccination among patients infected with covid-19. The vaccination type and number of doses had a significant association with outcomes.